Tyrosine kinase inhibitors for gastrointestinal stromal tumor after imatinib resistance

Gastrointestinal stromal tumors, common GI mesenchymal tumors, are driven by KIT/PDGFRA mutations. While imatinib significantly transformed treatment, resistance poses ongoing challenges. Subsequent approved therapies include sunitinib, regorafenib, and ripretinib. Avapritinib is notable for PDGFRA D842V mutations, and other agents and investigational compounds are being explored. Future strategies focus on precision medicine to overcome evolving resistance and optimize treatment.